Cargando…

Relapses in patients with Henoch–Schönlein purpura: Analysis of 417 patients from a single center

To further investigate into the relapses of Henoch–Schönlein purpura (HSP), we analyzed the frequency, clinical features, and predictors of relapses in series of 417 unselected patients from a single center. After a median follow-up of 12 (interquartile range [IQR]: 2–38) years, almost one-third of...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvo-Río, Vanesa, Hernández, José Luis, Ortiz-Sanjuán, Francisco, Loricera, Javier, Palmou-Fontana, Natalia, González-Vela, Maria C., González-Lamuño, Domingo, González-López, Marcos A., Armesto, Susana, Blanco, Ricardo, González-Gay, Miguel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956820/
https://www.ncbi.nlm.nih.gov/pubmed/27428226
http://dx.doi.org/10.1097/MD.0000000000004217
_version_ 1782444084750712832
author Calvo-Río, Vanesa
Hernández, José Luis
Ortiz-Sanjuán, Francisco
Loricera, Javier
Palmou-Fontana, Natalia
González-Vela, Maria C.
González-Lamuño, Domingo
González-López, Marcos A.
Armesto, Susana
Blanco, Ricardo
González-Gay, Miguel A.
author_facet Calvo-Río, Vanesa
Hernández, José Luis
Ortiz-Sanjuán, Francisco
Loricera, Javier
Palmou-Fontana, Natalia
González-Vela, Maria C.
González-Lamuño, Domingo
González-López, Marcos A.
Armesto, Susana
Blanco, Ricardo
González-Gay, Miguel A.
author_sort Calvo-Río, Vanesa
collection PubMed
description To further investigate into the relapses of Henoch–Schönlein purpura (HSP), we analyzed the frequency, clinical features, and predictors of relapses in series of 417 unselected patients from a single center. After a median follow-up of 12 (interquartile range [IQR]: 2–38) years, almost one-third of the 417 patients (n = 133; 32%; 85 men/48 women) had experienced at least 1 relapse. At the time of disease diagnosis, patients who later experienced relapses had less commonly infections than those who never suffered flares (30.8% vs 41.9%; P = 0.03). In contrast, patients who experienced relapses had a longer duration of the first episode of palpable purpura than those without relapses (palpable purpura lasting >7 days; 80.0% vs 68.1%; P = 0.04). Abdominal pain (72.3% vs 62.3%; P = 0.03) and joint manifestations (27.8% vs 15.5%; P = 0.005) were also more common in patients who later developed relapses. In contrast, patients who never suffered relapses had a slightly higher frequency of fever at the time of disease diagnosis (9.3% vs 3.8%; P = 0.06). At the time of disease diagnosis, corticosteroids were more frequently given to patients who later had relapses of the disease (44% vs 32% in nonrelapsing patients; P = 0.03). Relapses generally occurred soon after the first episode of vasculitis. The median time from the diagnosis of HSP to the first relapse was 1 (IQR: 1–2) month. The median number of relapses was 1 (IQR 1–3). The main clinical features at the time of the relapse were cutaneous (88.7%), gastrointestinal (27.1%), renal (24.8%), and joint (16.5%) manifestations. After a mean ± standard deviation follow-up of 18.9 ± 9.8 years, complete recovery was observed in 110 (82.7%) of the 133 patients who had relapses. Renal sequelae (persistent renal involvement) was found in 11 (8.3%) of the patients with relapses. The best predictive factors for relapse were joint and gastrointestinal manifestations at HSP diagnosis (odds ratio [OR]: 2.22; 95% confidence interval [CI]: 1.34–3.69, and OR: 1.60; 95% CI: 1.01–2.53, respectively). In contrast, a history of previous infection was a protective factor for relapses (OR: 0.60; 95% CI: 0.38–0.94). In conclusion, joint and gastrointestinal manifestations at the time of diagnosis of HSP are predictors of relapses.
format Online
Article
Text
id pubmed-4956820
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-49568202016-08-02 Relapses in patients with Henoch–Schönlein purpura: Analysis of 417 patients from a single center Calvo-Río, Vanesa Hernández, José Luis Ortiz-Sanjuán, Francisco Loricera, Javier Palmou-Fontana, Natalia González-Vela, Maria C. González-Lamuño, Domingo González-López, Marcos A. Armesto, Susana Blanco, Ricardo González-Gay, Miguel A. Medicine (Baltimore) 6900 To further investigate into the relapses of Henoch–Schönlein purpura (HSP), we analyzed the frequency, clinical features, and predictors of relapses in series of 417 unselected patients from a single center. After a median follow-up of 12 (interquartile range [IQR]: 2–38) years, almost one-third of the 417 patients (n = 133; 32%; 85 men/48 women) had experienced at least 1 relapse. At the time of disease diagnosis, patients who later experienced relapses had less commonly infections than those who never suffered flares (30.8% vs 41.9%; P = 0.03). In contrast, patients who experienced relapses had a longer duration of the first episode of palpable purpura than those without relapses (palpable purpura lasting >7 days; 80.0% vs 68.1%; P = 0.04). Abdominal pain (72.3% vs 62.3%; P = 0.03) and joint manifestations (27.8% vs 15.5%; P = 0.005) were also more common in patients who later developed relapses. In contrast, patients who never suffered relapses had a slightly higher frequency of fever at the time of disease diagnosis (9.3% vs 3.8%; P = 0.06). At the time of disease diagnosis, corticosteroids were more frequently given to patients who later had relapses of the disease (44% vs 32% in nonrelapsing patients; P = 0.03). Relapses generally occurred soon after the first episode of vasculitis. The median time from the diagnosis of HSP to the first relapse was 1 (IQR: 1–2) month. The median number of relapses was 1 (IQR 1–3). The main clinical features at the time of the relapse were cutaneous (88.7%), gastrointestinal (27.1%), renal (24.8%), and joint (16.5%) manifestations. After a mean ± standard deviation follow-up of 18.9 ± 9.8 years, complete recovery was observed in 110 (82.7%) of the 133 patients who had relapses. Renal sequelae (persistent renal involvement) was found in 11 (8.3%) of the patients with relapses. The best predictive factors for relapse were joint and gastrointestinal manifestations at HSP diagnosis (odds ratio [OR]: 2.22; 95% confidence interval [CI]: 1.34–3.69, and OR: 1.60; 95% CI: 1.01–2.53, respectively). In contrast, a history of previous infection was a protective factor for relapses (OR: 0.60; 95% CI: 0.38–0.94). In conclusion, joint and gastrointestinal manifestations at the time of diagnosis of HSP are predictors of relapses. Wolters Kluwer Health 2016-07-18 /pmc/articles/PMC4956820/ /pubmed/27428226 http://dx.doi.org/10.1097/MD.0000000000004217 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 6900
Calvo-Río, Vanesa
Hernández, José Luis
Ortiz-Sanjuán, Francisco
Loricera, Javier
Palmou-Fontana, Natalia
González-Vela, Maria C.
González-Lamuño, Domingo
González-López, Marcos A.
Armesto, Susana
Blanco, Ricardo
González-Gay, Miguel A.
Relapses in patients with Henoch–Schönlein purpura: Analysis of 417 patients from a single center
title Relapses in patients with Henoch–Schönlein purpura: Analysis of 417 patients from a single center
title_full Relapses in patients with Henoch–Schönlein purpura: Analysis of 417 patients from a single center
title_fullStr Relapses in patients with Henoch–Schönlein purpura: Analysis of 417 patients from a single center
title_full_unstemmed Relapses in patients with Henoch–Schönlein purpura: Analysis of 417 patients from a single center
title_short Relapses in patients with Henoch–Schönlein purpura: Analysis of 417 patients from a single center
title_sort relapses in patients with henoch–schönlein purpura: analysis of 417 patients from a single center
topic 6900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956820/
https://www.ncbi.nlm.nih.gov/pubmed/27428226
http://dx.doi.org/10.1097/MD.0000000000004217
work_keys_str_mv AT calvoriovanesa relapsesinpatientswithhenochschonleinpurpuraanalysisof417patientsfromasinglecenter
AT hernandezjoseluis relapsesinpatientswithhenochschonleinpurpuraanalysisof417patientsfromasinglecenter
AT ortizsanjuanfrancisco relapsesinpatientswithhenochschonleinpurpuraanalysisof417patientsfromasinglecenter
AT loricerajavier relapsesinpatientswithhenochschonleinpurpuraanalysisof417patientsfromasinglecenter
AT palmoufontananatalia relapsesinpatientswithhenochschonleinpurpuraanalysisof417patientsfromasinglecenter
AT gonzalezvelamariac relapsesinpatientswithhenochschonleinpurpuraanalysisof417patientsfromasinglecenter
AT gonzalezlamunodomingo relapsesinpatientswithhenochschonleinpurpuraanalysisof417patientsfromasinglecenter
AT gonzalezlopezmarcosa relapsesinpatientswithhenochschonleinpurpuraanalysisof417patientsfromasinglecenter
AT armestosusana relapsesinpatientswithhenochschonleinpurpuraanalysisof417patientsfromasinglecenter
AT blancoricardo relapsesinpatientswithhenochschonleinpurpuraanalysisof417patientsfromasinglecenter
AT gonzalezgaymiguela relapsesinpatientswithhenochschonleinpurpuraanalysisof417patientsfromasinglecenter